Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age

Stephen K. Tyring, Francisco Diaz-Mitoma, Larry G. Padget, Margarita Nunez, Gregory Poland, William M. Cassidy, Nickoya D. Bundick, Jianjun Li, Ivan S F Chan, Jon E. Stek, Paula W. Annunziato

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Herpes zoster (HZ) incidence rises with age, especially after 50 years of age, probably due to waning varicella-zoster virus (VZV)-specific immunity. The Shingles Prevention Study [Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med 2005;352:2271-84], enrolled people ≥60 years of age and showed that zoster vaccine prevents HZ and postherpetic neuralgia (PHN), presumably through boosting VZV-specific immunity. This study of people ≥50 years of age compared the safety and tolerability of two zoster vaccine potencies. Methods: Adults ≥50 years old enrolled in a randomized, double-blind, multicenter study to compare the safety and tolerability of one dose of two zoster vaccine potencies, ∼58,000 and ∼207,000 plaque-forming units/dose. Adverse experiences (AEs) were recorded on a standardized Vaccination Report Card for 42 days postvaccination. For assessment of injection-site AEs, clinically acceptable tolerability was predefined based on experience with PNEUMOVAX™ 23, a licensed vaccine recommended for use in older people. Results: Six hundred and ninety-eight subjects (age 50-90 years, median 64 years) were enrolled. No serious vaccine-related AEs were reported. Similar AE rates were observed in the higher and lower potency groups (overall systemic AEs: 37.5 and 39.3%, vaccine-related systemic AEs: 10.9 and 13.2%, injection-site AEs: 63.0 and 59.8%). Rates for a combined endpoint of moderate or severe injection-site pain/tenderness/soreness and swelling were 17.2% (95% CI 13.9, 21.0) and 9.0% (95% CI 5.6, 13.4), respectively. Most combined endpoint events were reported as moderate in intensity. Conclusions: Both vaccine potencies were generally well tolerated in this study of people ≥50 years of age. Although rates of some moderate or severe injection-site AEs were greater in the higher potency group, all rates met the prespecified criteria for clinically acceptable tolerability.

Original languageEnglish (US)
Pages (from-to)1877-1883
Number of pages7
JournalVaccine
Volume25
Issue number10
DOIs
StatePublished - Feb 26 2007

Fingerprint

Herpes Zoster Vaccine
Vaccine Potency
Herpes Zoster
Vaccines
vaccines
Postherpetic Neuralgia
Safety
Injections
Human Herpesvirus 3
injection site
Immunity
Human herpesvirus 3
endpoints
Double-Blind Method
Multicenter Studies
Vaccination
immunity
Pain
Incidence
dosage

Keywords

  • Safety
  • Tolerability
  • Zoster vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Tyring, S. K., Diaz-Mitoma, F., Padget, L. G., Nunez, M., Poland, G., Cassidy, W. M., ... Annunziato, P. W. (2007). Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine, 25(10), 1877-1883. https://doi.org/10.1016/j.vaccine.2006.10.027

Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. / Tyring, Stephen K.; Diaz-Mitoma, Francisco; Padget, Larry G.; Nunez, Margarita; Poland, Gregory; Cassidy, William M.; Bundick, Nickoya D.; Li, Jianjun; Chan, Ivan S F; Stek, Jon E.; Annunziato, Paula W.

In: Vaccine, Vol. 25, No. 10, 26.02.2007, p. 1877-1883.

Research output: Contribution to journalArticle

Tyring, SK, Diaz-Mitoma, F, Padget, LG, Nunez, M, Poland, G, Cassidy, WM, Bundick, ND, Li, J, Chan, ISF, Stek, JE & Annunziato, PW 2007, 'Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age', Vaccine, vol. 25, no. 10, pp. 1877-1883. https://doi.org/10.1016/j.vaccine.2006.10.027
Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM et al. Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. Vaccine. 2007 Feb 26;25(10):1877-1883. https://doi.org/10.1016/j.vaccine.2006.10.027
Tyring, Stephen K. ; Diaz-Mitoma, Francisco ; Padget, Larry G. ; Nunez, Margarita ; Poland, Gregory ; Cassidy, William M. ; Bundick, Nickoya D. ; Li, Jianjun ; Chan, Ivan S F ; Stek, Jon E. ; Annunziato, Paula W. / Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age. In: Vaccine. 2007 ; Vol. 25, No. 10. pp. 1877-1883.
@article{d655de1482a441e3aac9f78978408961,
title = "Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age",
abstract = "Background: Herpes zoster (HZ) incidence rises with age, especially after 50 years of age, probably due to waning varicella-zoster virus (VZV)-specific immunity. The Shingles Prevention Study [Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med 2005;352:2271-84], enrolled people ≥60 years of age and showed that zoster vaccine prevents HZ and postherpetic neuralgia (PHN), presumably through boosting VZV-specific immunity. This study of people ≥50 years of age compared the safety and tolerability of two zoster vaccine potencies. Methods: Adults ≥50 years old enrolled in a randomized, double-blind, multicenter study to compare the safety and tolerability of one dose of two zoster vaccine potencies, ∼58,000 and ∼207,000 plaque-forming units/dose. Adverse experiences (AEs) were recorded on a standardized Vaccination Report Card for 42 days postvaccination. For assessment of injection-site AEs, clinically acceptable tolerability was predefined based on experience with PNEUMOVAX™ 23, a licensed vaccine recommended for use in older people. Results: Six hundred and ninety-eight subjects (age 50-90 years, median 64 years) were enrolled. No serious vaccine-related AEs were reported. Similar AE rates were observed in the higher and lower potency groups (overall systemic AEs: 37.5 and 39.3{\%}, vaccine-related systemic AEs: 10.9 and 13.2{\%}, injection-site AEs: 63.0 and 59.8{\%}). Rates for a combined endpoint of moderate or severe injection-site pain/tenderness/soreness and swelling were 17.2{\%} (95{\%} CI 13.9, 21.0) and 9.0{\%} (95{\%} CI 5.6, 13.4), respectively. Most combined endpoint events were reported as moderate in intensity. Conclusions: Both vaccine potencies were generally well tolerated in this study of people ≥50 years of age. Although rates of some moderate or severe injection-site AEs were greater in the higher potency group, all rates met the prespecified criteria for clinically acceptable tolerability.",
keywords = "Safety, Tolerability, Zoster vaccine",
author = "Tyring, {Stephen K.} and Francisco Diaz-Mitoma and Padget, {Larry G.} and Margarita Nunez and Gregory Poland and Cassidy, {William M.} and Bundick, {Nickoya D.} and Jianjun Li and Chan, {Ivan S F} and Stek, {Jon E.} and Annunziato, {Paula W.}",
year = "2007",
month = "2",
day = "26",
doi = "10.1016/j.vaccine.2006.10.027",
language = "English (US)",
volume = "25",
pages = "1877--1883",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Safety and tolerability of a high-potency zoster vaccine in adults ≥50 years of age

AU - Tyring, Stephen K.

AU - Diaz-Mitoma, Francisco

AU - Padget, Larry G.

AU - Nunez, Margarita

AU - Poland, Gregory

AU - Cassidy, William M.

AU - Bundick, Nickoya D.

AU - Li, Jianjun

AU - Chan, Ivan S F

AU - Stek, Jon E.

AU - Annunziato, Paula W.

PY - 2007/2/26

Y1 - 2007/2/26

N2 - Background: Herpes zoster (HZ) incidence rises with age, especially after 50 years of age, probably due to waning varicella-zoster virus (VZV)-specific immunity. The Shingles Prevention Study [Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med 2005;352:2271-84], enrolled people ≥60 years of age and showed that zoster vaccine prevents HZ and postherpetic neuralgia (PHN), presumably through boosting VZV-specific immunity. This study of people ≥50 years of age compared the safety and tolerability of two zoster vaccine potencies. Methods: Adults ≥50 years old enrolled in a randomized, double-blind, multicenter study to compare the safety and tolerability of one dose of two zoster vaccine potencies, ∼58,000 and ∼207,000 plaque-forming units/dose. Adverse experiences (AEs) were recorded on a standardized Vaccination Report Card for 42 days postvaccination. For assessment of injection-site AEs, clinically acceptable tolerability was predefined based on experience with PNEUMOVAX™ 23, a licensed vaccine recommended for use in older people. Results: Six hundred and ninety-eight subjects (age 50-90 years, median 64 years) were enrolled. No serious vaccine-related AEs were reported. Similar AE rates were observed in the higher and lower potency groups (overall systemic AEs: 37.5 and 39.3%, vaccine-related systemic AEs: 10.9 and 13.2%, injection-site AEs: 63.0 and 59.8%). Rates for a combined endpoint of moderate or severe injection-site pain/tenderness/soreness and swelling were 17.2% (95% CI 13.9, 21.0) and 9.0% (95% CI 5.6, 13.4), respectively. Most combined endpoint events were reported as moderate in intensity. Conclusions: Both vaccine potencies were generally well tolerated in this study of people ≥50 years of age. Although rates of some moderate or severe injection-site AEs were greater in the higher potency group, all rates met the prespecified criteria for clinically acceptable tolerability.

AB - Background: Herpes zoster (HZ) incidence rises with age, especially after 50 years of age, probably due to waning varicella-zoster virus (VZV)-specific immunity. The Shingles Prevention Study [Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N Engl J Med 2005;352:2271-84], enrolled people ≥60 years of age and showed that zoster vaccine prevents HZ and postherpetic neuralgia (PHN), presumably through boosting VZV-specific immunity. This study of people ≥50 years of age compared the safety and tolerability of two zoster vaccine potencies. Methods: Adults ≥50 years old enrolled in a randomized, double-blind, multicenter study to compare the safety and tolerability of one dose of two zoster vaccine potencies, ∼58,000 and ∼207,000 plaque-forming units/dose. Adverse experiences (AEs) were recorded on a standardized Vaccination Report Card for 42 days postvaccination. For assessment of injection-site AEs, clinically acceptable tolerability was predefined based on experience with PNEUMOVAX™ 23, a licensed vaccine recommended for use in older people. Results: Six hundred and ninety-eight subjects (age 50-90 years, median 64 years) were enrolled. No serious vaccine-related AEs were reported. Similar AE rates were observed in the higher and lower potency groups (overall systemic AEs: 37.5 and 39.3%, vaccine-related systemic AEs: 10.9 and 13.2%, injection-site AEs: 63.0 and 59.8%). Rates for a combined endpoint of moderate or severe injection-site pain/tenderness/soreness and swelling were 17.2% (95% CI 13.9, 21.0) and 9.0% (95% CI 5.6, 13.4), respectively. Most combined endpoint events were reported as moderate in intensity. Conclusions: Both vaccine potencies were generally well tolerated in this study of people ≥50 years of age. Although rates of some moderate or severe injection-site AEs were greater in the higher potency group, all rates met the prespecified criteria for clinically acceptable tolerability.

KW - Safety

KW - Tolerability

KW - Zoster vaccine

UR - http://www.scopus.com/inward/record.url?scp=33846582989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846582989&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.10.027

DO - 10.1016/j.vaccine.2006.10.027

M3 - Article

C2 - 17227688

AN - SCOPUS:33846582989

VL - 25

SP - 1877

EP - 1883

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 10

ER -